Human disease modeling using somatic gene transfer
OwnerRonald Klein, Edwin M Meyer +3inventors
InventorsRonald Klein, Edwin M Meyer, Nicholas Muzyczka, Michael A King, Craig A Meyers
Life of this patent
Estimating the term…
Abstract
The invention provides a system for modeling neurodegenerative and other diseases through somatic gene transfer. In addition, methods of multiple gene transfer, disease analysis and drug testing are provided for.
Claims23
A method for producing a non-human animal model of a human disease which comprises transferring at least one aberrant form of at least one gene known to be associated with said disease in humans into appropriate tissue of a living non-human animal under conditions which result in the expression of said at least one aberrant gene, wherein said transferring does not require the modification of the germ-line of said living animal.
A method for inducing neurofibrillary tangles in the brain of a non-human animal which comprises injecting into the brain of said animal an effective amount of a gene expression construct encoding tau, alpha-synuclein, presenilin-1, amyloid precursor protein, IL6, or a combination thereof.
A method for inducing behavioral changes in a non-human animal model which comprises somatic administration of at least one gene directly to the brain of said non-human animal, wherein said at least one gene is associated with a human neurodegenerative disease.
A method of identifying a pharmacologically active substance that slows, reduces, reverses or eliminates the adverse effects of a degenerative neurological disease, comprising:
- a. transferring at least one aberrant form of at least one gene known to be associated with said disease in humans into appropriate tissue of a living non-human animal under conditions which result in the expression of said at least one aberrant gene, wherein said transferring does not require the modification of the germ-line of said living animal;
- b. repeating step “a” for a sufficient number of living non-human animals to evaluate a desired number of pharmacologically active substances at a desired number of concentrations, combinations, administration regimes, and evaluation schedules;
- c. exposing a specified number of said sufficient number of living non-human animals of step “b” to a specific pharmacologically active substance at a desired number of concentrations and administration regimes, and optionally repeating this exposing for each of a desired number of additional specific pharmacologically active substance(s);
- and
- d. evaluating said specific pharmacologically active substance(s) of step “c”;
- wherein said evaluating provides information that identifies at least one pharmacologically active substance that slows, reduces or eliminates the adverse effects of a degenerative neurological disease.
A method of identifying a nutrient regime that slows, reduces, reverses or eliminates the adverse effects of a degenerative neurological disease, comprising:
- a. transferring at least one aberrant form of at least one gene known to be associated with said disease in humans into appropriate tissue of a living non-human animal under conditions which result in the expression of said at least one aberrant gene, wherein said transferring does not require the modification of the germ-line of said living animal;
- b. repeating step “a” for a sufficient number of living non-human animals to evaluate a desired number of pharmacologically active substances at a desired number of concentrations, combinations, administration regimes, and evaluation schedules;
- c. exposing a specified number of said sufficient number of living non-human animals of step “b” to a specific pharmacologically active substance at a desired number of concentrations and administration regimes, and optionally repeating this exposing for each of a desired number of additional specific pharmacologically active substance(s);
- and
- d. evaluating said specific pharmacologically active substance(s) of step “c”;
- wherein said evaluating provides information that identifies at least one pharmacologically active substance that slows, reduces or eliminates the adverse effects of a degenerative neurological disease.
A method of identifying an environmental inducer that aggravates, induces, or otherwise contributes to the adverse effects of a degenerative neurological disease, comprising:
- a. transferring at least one aberrant form of at least one gene known to be associated with said disease in humans into appropriate tissue of a living non-human animal under conditions which result in the expression of said at least one aberrant gene, wherein said transferring does not require the modification of the germ-line of said living animal;
- b. repeating step “a” for a sufficient number of living non-human animals to evaluate a desired number of pharmacologically active substances at a desired number of concentrations, combinations, administration regimes, and evaluation schedules;
- c. exposing a specified number of said sufficient number of living non-human animals of step “b” to a specific environmental inducer at a desired number of concentrations and administration regimes, and optionally repeating this exposing for each of a desired number of additional specific environmental inducer(s);
- and
- d. evaluating said specific environmental inducer(s) of step “c”;
- wherein said evaluating provides information that identifies at least one environmental inducer that aggravates, induces, or otherwise contributes to the adverse effects of a degenerative neurological disease.
Dependencies are inferred from the claim text.